Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00028288 · ClinicalTrials.gov registry record · Phase 2
Study of Daclizumab in Patients With Chronic, Persistent Asthma
A Phase 2 study, sponsored by Facet Biotech.
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
NCT00028288 is a Phase 2 study that has completed, run by Facet Biotech. The registered enrollment target is 120 participants.
The verdict
NCT00028288, a Phase 2 study, has completed, sponsored by Facet Biotech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate an investigational medication to treat chronic persistent asthma. The research is being conducted at up to 22 clinical research sites in the US and is open to both men and women ages 18 to 70 years old. Participants in the study will have a number of visits to a research site over a 10-month period. All study-related care and medication is provided to qualified participants at no cost: this includes all visits, examinations and laboratory work.
Interventions
- DRUG Daclizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2001-09 |
| Est. Completion | 2003-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00028288
The ClinicalTrials.gov registry entry for NCT00028288 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Facet Biotech, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Daclizumab is the first listed.
NCT00028288 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00028288 about?
NCT00028288 is a clinical study titled "Study of Daclizumab in Patients With Chronic, Persistent Asthma". The purpose of the study is to evaluate an investigational medication to treat chronic persistent asthma. The research is being conducted at up to 22 clinical research sites in the US and is open to both men and women ages 18 to 70 years old. Participants in the study will have a number of visits to...
What is the current status of trial NCT00028288?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2001-09. Estimated completion is 2003-12.
What interventions are being tested in trial NCT00028288?
The interventions under investigation include: Daclizumab (DRUG).
Who is sponsoring clinical trial NCT00028288?
This trial is sponsored by Facet Biotech, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.